Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Sberbank launches biometric payment across Russia

6/2/23 SBER

Etalon opened sales in a new project in St. Petersburg

6/2/23 ETLN

Broadcom announced a quarterly dividend

6/2/23 AVGO

Price placement of VTB shares will be ₽0.018225

6/2/23 VTBR

Sitronics Group unveils double-deck electric catamaran

6/2/23 AFKS

GAZ may start producing cars under the Volga brand

6/2/23 GAZA

Sitronics Group will equip the Port of Sochi with the first Russian ship traffic control system

6/2/23 AFKS

Broadcom reported for 6 months of fiscal year 2023

6/2/23 AVGO

Sitronics Group plans to build a hydrogen-powered ship by the end of summer

6/2/23 AFKS

Sollers expects to increase sales by 12% in 2023

6/1/23 SVAV